October 26, 2020 07:00 AM EDTUpdated 10:59 AM

Covid-19 roundup: AstraZeneca's candidate could elicit immune response in older patients; The EMA could approve a vaccine with less than 50% efficacy — report

Nicole DeFeudis

Editor

With permission to resume its Covid-19 trial in the US, AstraZeneca is back in the race for emergency approval. And early results suggest the candidate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: AstraZeneca's candidate could elicit immune response in older patients; The EMA could approve a vaccine with less than 50% efficacy — report

Nicole DeFeudis

Editor

Sign up to read this article for free.

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Covid-19 roundup: As­traZeneca's can­di­date could elic­it im­mune re­sponse in old­er pa­tients; The EMA could ap­prove a vac­cine with less than 50% ef­fi­ca­cy — re­port

Nicole DeFeudis

Editor

Sign up to read this article for free.

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Covid-19 roundup: AstraZeneca's candidate could elicit immune response in older patients; The EMA could approve a vaccine with less than 50% efficacy — report

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?